Related references
Note: Only part of the references are listed.Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara
Guus F. Rimmelzwaan et al.
EXPERT REVIEW OF VACCINES (2009)
Recombinant Modified Vaccinia Virus Ankara Expressing the Hemagglutinin Gene Confers Protection against Homologous and Heterologous H5N1 Influenza Virus Infections in Macaques
J. H. C. M. Kreijtz et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer
Carmen E. Gomez et al.
CURRENT GENE THERAPY (2008)
Vaccination of Macaques with adjuvanted formalin-inactivated influenza a virus (H5N1) vaccines: Protection against H5N1 challenge without disease enhancement
Caroline Ruat et al.
JOURNAL OF VIROLOGY (2008)
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial
Isabel Leroux-Roels et al.
LANCET (2007)
Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses
Otfried Kistner et al.
VACCINE (2007)
Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1
Joost H. C. M. Kreijtz et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines
Bernd Kalbfuss et al.
BIOTECHNOLOGY AND BIOENGINEERING (2007)
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial
Jiangtao Lin et al.
LANCET (2006)
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial
Richard Harrop et al.
CLINICAL CANCER RESEARCH (2006)
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
Jean-Louis Bresson et al.
LANCET (2006)
Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture
N Nwe et al.
BMC MICROBIOLOGY (2006)
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
MA Hoelscher et al.
LANCET (2006)
Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization
WT Gao et al.
JOURNAL OF VIROLOGY (2006)
Making better influenza virus vaccines?
P Palese
EMERGING INFECTIOUS DISEASES (2006)
Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain
E de Wit et al.
JOURNAL OF VIROLOGY (2005)
Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system
C Nicolson et al.
VACCINE (2005)
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
I Drexler et al.
CURRENT OPINION IN BIOTECHNOLOGY (2004)
Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals
A Cosma et al.
VACCINE (2003)
Are we ready for pandemic influenza?
RJ Webby et al.
SCIENCE (2003)
Overcoming immunity to a viral vaccine by DNA priming before vector boosting
ZY Yang et al.
JOURNAL OF VIROLOGY (2003)
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
KG Nicholson et al.
LANCET (2001)
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques
KJ Stittelaar et al.
VACCINE (2001)
Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans
JJ Treanor et al.
VACCINE (2001)
Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector
JC Ramírez et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
